ACAD
47.76
-0.84
-1.73%
AEMD
10.164
+0.614
+6.429%
APRI
1.46
-0.03
-2.01%
ARNA
3.91
-0.18
-4.40%
ATEC
1.39
+0.03
+2.21%
CNAT
4.81
-0.12
-2.43%
CRXM
0.27
-0.03
-11.65%
CYTX
0.426
-0.014
-3.0909%
DXCM
84.2
+0.64
+0.77%
GNMK
8.41
-0.34
-3.89%
HALO
23.14
-0.29
-1.24%
ILMN
218.39
+1.2
+0.55%
INNV
0.155
0.00
0.00%
INO
7.225
-0.175
-2.365%
ISCO
0.043
0.00
0.00%
ISIS
53.17
+0.12
+0.23%
LGND
107.75
+0.89
+0.83%
LPTN
0.265
-0.01
-3.566%
MBVX
1.94
+0.14
+7.78%
MEIP
1.61
-0.04
-2.42%
MNOV
3.7
-0.17
-4.39%
MRTX
27.24
-0.22
-0.80%
MSTX
0.45
-0.004
-0.9467%
NBIX
50.02
-0.64
-1.26%
NUVA
54.92
+0.33
+0.60%
ONCS
6.11
-0.06
-0.97%
ONVO
3.39
-0.15
-4.24%
OREX
3.97
+0.06
+1.53%
OTIC
25.47
-0.64
-2.45%
QDEL
21.025
-0.445
-2.073%
RCPT
227.48
-0.16
-0.07%
RGLS
8.22
+0.03
+0.37%
RMD
56.18
+0.26
+0.46%
SCIE
0.02
0.00
0.00%
SPHS
0.88
-0.02
-2.21%
SRNE
20.44
+1.24
+6.46%
TROV
7.76
-0.25
-3.12%
VICL
0.64
0.00
+0.27%
ZGNX
19.29
+0.8
+4.33%
ACAD
47.76
-0.84
-1.73%
AEMD
10.164
+0.614
+6.429%
APRI
1.46
-0.03
-2.01%
ARNA
3.91
-0.18
-4.40%
ATEC
1.39
+0.03
+2.21%
CNAT
4.81
-0.12
-2.43%
CRXM
0.27
-0.03
-11.65%
CYTX
0.426
-0.014
-3.0909%
DXCM
84.2
+0.64
+0.77%
GNMK
8.41
-0.34
-3.89%
HALO
23.14
-0.29
-1.24%
ILMN
218.39
+1.2
+0.55%
INNV
0.155
0.00
0.00%
INO
7.225
-0.175
-2.365%
ISCO
0.043
0.00
0.00%
ISIS
53.17
+0.12
+0.23%
LGND
107.75
+0.89
+0.83%
LPTN
0.265
-0.01
-3.566%
MBVX
1.94
+0.14
+7.78%
MEIP
1.61
-0.04
-2.42%
MNOV
3.7
-0.17
-4.39%
MRTX
27.24
-0.22
-0.80%
MSTX
0.45
-0.004
-0.9467%
NBIX
50.02
-0.64
-1.26%
NUVA
54.92
+0.33
+0.60%
ONCS
6.11
-0.06
-0.97%
ONVO
3.39
-0.15
-4.24%
OREX
3.97
+0.06
+1.53%
OTIC
25.47
-0.64
-2.45%
QDEL
21.025
-0.445
-2.073%
RCPT
227.48
-0.16
-0.07%
RGLS
8.22
+0.03
+0.37%
RMD
56.18
+0.26
+0.46%
SCIE
0.02
0.00
0.00%
SPHS
0.88
-0.02
-2.21%
SRNE
20.44
+1.24
+6.46%
TROV
7.76
-0.25
-3.12%
VICL
0.64
0.00
+0.27%
ZGNX
19.29
+0.8
+4.33%
Home » Archive by Category

Syndication

Crafting the Perfect Brew

December 11, 2014 – 7:00 am

George Thornton made his first batch of beer at his sister’s apartment, using the spare bedroom to store the fermenting ale. Today, the UC San Diego alumnus is the owner of The Homebrewer in North Park, a supply store and educational resource for both beginning and advanced homebrewers. Here, customers can choose from a variety of hops, yeast, grains, additives and equipment, as well as participate in classes taught by fellow homebrewers. Next year, Thornton will open a small production brewery and tasting room next door.

MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase

December 11, 2014 – 6:30 am

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is scheduled to present at 9:00 am on Wednesday, January 14th in the Powell presentation room at the Parc 55 Wyndham Hotel in San Francisco.  MabVax will present a corporate update including highlighting the significant progress made in the last year on the development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer.  MabVax’s CEO David Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials.  He will also discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax received an Orphan Drug Designation from FDA in September of this year.

About HuMab 5B1

Recently MabVax nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.  The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials.   One program will be aimed at demonstrating the utility of the radiolabeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer.  The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.  

About MabVax

MabVax Therapeutics Holdings, Inc. is cancer diagnostic and immunotherapy company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center.  MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.

Additional information about the Company is available at www.mabvax.com.

Forward Looking Statements

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s development pipeline and stock symbol.  We have no assurance that all of the product development pipeline will be fully developed by the Company.   Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2013 and in the Proxy Statement dated July 25, 2014, as amended and supplemented from time to time and in our quarterly report on Form 10-Q for June 30, 2014.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

SOURCE MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase

December 11, 2014 – 6:30 am

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is scheduled to present at 9:00 am on Wednesday, January 14th in the Powell presentation room at the Parc 55 Wyndham Hotel in San Francisco.  MabVax will present a corporate update including highlighting the significant progress made in the last year on the development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer.  MabVax’s CEO David Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials.  He will also discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax received an Orphan Drug Designation from FDA in September of this year.

About HuMab 5B1

Recently MabVax nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.  The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials.   One program will be aimed at demonstrating the utility of the radiolabeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer.  The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.  

About MabVax

MabVax Therapeutics Holdings, Inc. is cancer diagnostic and immunotherapy company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center.  MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.

Additional information about the Company is available at www.mabvax.com.

Forward Looking Statements

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s development pipeline and stock symbol.  We have no assurance that all of the product development pipeline will be fully developed by the Company.   Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2013 and in the Proxy Statement dated July 25, 2014, as amended and supplemented from time to time and in our quarterly report on Form 10-Q for June 30, 2014.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

SOURCE MabVax Therapeutics Holdings, Inc.

Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study

December 11, 2014 – 5:15 am

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.

The Aethlon Hemopurifier is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, Hemopurifier therapy has been administered outside the United States in the treatment of Ebola, HIV and HCV-infected individuals.

Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications.

The feasibility study will also contribute safety data to advance Hemopurifier therapy as a broad-spectrum countermeasure against category “A” bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies. The virulence of such viral threats does not permit for human pivotal (efficacy) studies to be conducted. In the treatment of Ebola virus, Hemopurifier therapy is available in the US under emergency-use IDE regulatory provisions. The Company plans to pursue Humanitarian Use Device (HUD) approval pathways for Ebola and orphan indications that affect fewer than 4,000 individuals in the U.S. each year.

Previously, in vitro studies of bioterror and pandemic threats have verified Hemopurifier capture of Ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non-government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Aethlon Media Contact:Leah-Michelle Nebbia (for interviews requests)Golin202-585-2651lnebbia@golin.com

James A. JoyceChairman and CEO(Office) 858.459.7800 x301(Cell) 619-368-2000jj@aethlonmedical.com

Jim FrakesChief Financial Officer858.459.7800 x300jfrakes@aethlonmedical.com 

Photo – http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

SOURCE Aethlon Medical, Inc.

Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study

December 11, 2014 – 5:15 am

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.

The Aethlon Hemopurifier is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, Hemopurifier therapy has been administered outside the United States in the treatment of Ebola, HIV and HCV-infected individuals.

Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications.

The feasibility study will also contribute safety data to advance Hemopurifier therapy as a broad-spectrum countermeasure against category “A” bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies. The virulence of such viral threats does not permit for human pivotal (efficacy) studies to be conducted. In the treatment of Ebola virus, Hemopurifier therapy is available in the US under emergency-use IDE regulatory provisions. The Company plans to pursue Humanitarian Use Device (HUD) approval pathways for Ebola and orphan indications that affect fewer than 4,000 individuals in the U.S. each year.

Previously, in vitro studies of bioterror and pandemic threats have verified Hemopurifier capture of Ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non-government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Aethlon Media Contact:Leah-Michelle Nebbia (for interviews requests)Golin202-585-2651lnebbia@golin.com

James A. JoyceChairman and CEO(Office) 858.459.7800 x301(Cell) 619-368-2000jj@aethlonmedical.com

Jim FrakesChief Financial Officer858.459.7800 x300jfrakes@aethlonmedical.com 

Photo – http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

SOURCE Aethlon Medical, Inc.

Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study

December 11, 2014 – 5:15 am

SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.

The Aethlon Hemopurifier is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, Hemopurifier therapy has been administered outside the United States in the treatment of Ebola, HIV and HCV-infected individuals.

Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications.

The feasibility study will also contribute safety data to advance Hemopurifier therapy as a broad-spectrum countermeasure against category “A” bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies. The virulence of such viral threats does not permit for human pivotal (efficacy) studies to be conducted. In the treatment of Ebola virus, Hemopurifier therapy is available in the US under emergency-use IDE regulatory provisions. The Company plans to pursue Humanitarian Use Device (HUD) approval pathways for Ebola and orphan indications that affect fewer than 4,000 individuals in the U.S. each year.

Previously, in vitro studies of bioterror and pandemic threats have verified Hemopurifier capture of Ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non-government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Aethlon Media Contact:Leah-Michelle Nebbia (for interviews requests)Golin202-585-2651lnebbia@golin.com

James A. JoyceChairman and CEO(Office) 858.459.7800 x301(Cell) 619-368-2000jj@aethlonmedical.com

Jim FrakesChief Financial Officer858.459.7800 x300jfrakes@aethlonmedical.com 

Photo – http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

SOURCE Aethlon Medical, Inc.

Contracts Paralegal – AnaptysBio, Inc. – San Diego, CA

December 10, 2014 – 11:08 pm

Maintaining company databases in paper and electronic format in accordance with document control processes, including managing agreement expirations and…
From DeviceSpace.com – 11 Dec 2014 14:54:00 GMT
– View all San Diego jobs

Field Sales – Direct Sales – Specialist – EMD Group – San Diego, CA

December 10, 2014 – 11:08 pm

Three to 5 years of experience within pharmaceutical development or technology implementation is a plus….
From BioSpace.com – 12 Dec 2014 08:58:03 GMT
– View all San Diego jobs

Account Manager-Life Sciences

December 10, 2014 – 10:00 pm

Details: Purpose: (In a brief statement, indicate the overall purpose of this position) The Account Manager will be responsible for the achievement of the annual sales (orders) revenue plan for the designated territory, as well as field service such as product demonstrations and minor product repairs. The main responsibility will be to win new highly profitable opportunities. About Xylem: Xylem (incorporated in the USA, stock symbol: XYL) is a leading global water technology provider, enabling customers to transport, treat, test and efficiently use water in public utility, residential and commercial building services, industrial and agricultural settings. The company does business in more than 150 countries through a number of market-leading product brands, and its people bring broad applications expertise with a strong focus on finding local solutions to the world’s most challenging water and wastewater problems. Launched in 2011 from the spinoff of the water-related businesses of ITT Corporation, Xylem is headquartered in White Plains, N.Y., with annual revenues of $3.8 billion and 12,500 employees worldwide. About Xylem Analytics: Xylem’s analytics businesses are leading manufacturers of premium field, portable, laboratory and online analytical instruments used in water and wastewater, environmental, medical, food and beverage and life science applications. The company’s meters, sensors, analyzers and related consumables are used every day by thousands of end-users worldwide to analyze and control quality in countless industrial applications where precise measurement is required. Xylem’s analytics business has been created over the past two years with the acquisitions of OI Analytical, YSI and MJK Automation to their core businesses of WTW, SI Analytics, Aanderaa Data Instruments (AADI), Global Water Instrumentation, ebro and Bellingham & Stanley. www.xylemanalytics.com Major Responsibilities: • Track performance against defined individual territory budget to meet or exceed growth objectives • Support customers with up to date training, product bulletins and key account development • Develop relationships with customer buying influences. • Develop and submit monthly reports based on territory performance. Additional Responsibilities: • Compile and report monthly sales updates for territory • 60-70% overnight travel required to fulfill sales obligations Qualifications: • Bachelor’s degree in a science field. • Seven to 10 years experience, 3 of which must be in sales • Previous experience selling analytical instruments in bio-tech or bio-pharma markets a plus. Competencies: • Action oriented with strong background in business • Ability to work with all levels of the organization • Presentation skills • Problem solving • Time management Attendance Requirements: 40 hours/week and additional hours as required Tasks: (on-going duties) • Marketing Support: • Support new product launches • Provide feedback on competitive products & strategy • Support LS attendance at trade shows as needed: • Provide market feedback for new product launch • Provide market feedback on product acceptance & performance Customer & Technical Service: – Resolve customer disputes with input from US Sales Mgr – Provide customer training as needed Disclaimer: The above information on this description has been designed to indicate the general nature and level of work performed by employees within this classification. It is not designed to contain or be interpreted as a comprehensive inventory of all duties, responsibilities, and qualifications required of employees assigned to this job. YSI Incorporated (a xylem brand) provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, creed, color, sex, religion, sexual orientation, national origin, pregnancy, age, medical condition, disability, national origin, ancestry, citizenship status, genetic information, marital status, amnesty, or status as a covered uniformed service member/veteran (military) in accordance with applicable federal, state and local laws. YSI complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Account Manager-Life Sciences

December 10, 2014 – 10:00 pm

Details: Purpose: (In a brief statement, indicate the overall purpose of this position) The Account Manager will be responsible for the achievement of the annual sales (orders) revenue plan for the designated territory, as well as field service such as product demonstrations and minor product repairs. The main responsibility will be to win new highly profitable opportunities. About Xylem: Xylem (incorporated in the USA, stock symbol: XYL) is a leading global water technology provider, enabling customers to transport, treat, test and efficiently use water in public utility, residential and commercial building services, industrial and agricultural settings. The company does business in more than 150 countries through a number of market-leading product brands, and its people bring broad applications expertise with a strong focus on finding local solutions to the world’s most challenging water and wastewater problems. Launched in 2011 from the spinoff of the water-related businesses of ITT Corporation, Xylem is headquartered in White Plains, N.Y., with annual revenues of $3.8 billion and 12,500 employees worldwide. About Xylem Analytics: Xylem’s analytics businesses are leading manufacturers of premium field, portable, laboratory and online analytical instruments used in water and wastewater, environmental, medical, food and beverage and life science applications. The company’s meters, sensors, analyzers and related consumables are used every day by thousands of end-users worldwide to analyze and control quality in countless industrial applications where precise measurement is required. Xylem’s analytics business has been created over the past two years with the acquisitions of OI Analytical, YSI and MJK Automation to their core businesses of WTW, SI Analytics, Aanderaa Data Instruments (AADI), Global Water Instrumentation, ebro and Bellingham & Stanley. www.xylemanalytics.com Major Responsibilities: • Track performance against defined individual territory budget to meet or exceed growth objectives • Support customers with up to date training, product bulletins and key account development • Develop relationships with customer buying influences. • Develop and submit monthly reports based on territory performance. Additional Responsibilities: • Compile and report monthly sales updates for territory • 60-70% overnight travel required to fulfill sales obligations Qualifications: • Bachelor’s degree in a science field. • Seven to 10 years experience, 3 of which must be in sales • Previous experience selling analytical instruments in bio-tech or bio-pharma markets a plus. Competencies: • Action oriented with strong background in business • Ability to work with all levels of the organization • Presentation skills • Problem solving • Time management Attendance Requirements: 40 hours/week and additional hours as required Tasks: (on-going duties) • Marketing Support: • Support new product launches • Provide feedback on competitive products & strategy • Support LS attendance at trade shows as needed: • Provide market feedback for new product launch • Provide market feedback on product acceptance & performance Customer & Technical Service: – Resolve customer disputes with input from US Sales Mgr – Provide customer training as needed Disclaimer: The above information on this description has been designed to indicate the general nature and level of work performed by employees within this classification. It is not designed to contain or be interpreted as a comprehensive inventory of all duties, responsibilities, and qualifications required of employees assigned to this job. YSI Incorporated (a xylem brand) provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, creed, color, sex, religion, sexual orientation, national origin, pregnancy, age, medical condition, disability, national origin, ancestry, citizenship status, genetic information, marital status, amnesty, or status as a covered uniformed service member/veteran (military) in accordance with applicable federal, state and local laws. YSI complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.